JP2020507577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507577A5 JP2020507577A5 JP2019543270A JP2019543270A JP2020507577A5 JP 2020507577 A5 JP2020507577 A5 JP 2020507577A5 JP 2019543270 A JP2019543270 A JP 2019543270A JP 2019543270 A JP2019543270 A JP 2019543270A JP 2020507577 A5 JP2020507577 A5 JP 2020507577A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- variable domain
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 102000004169 proteins and genes Human genes 0.000 claims description 68
- 239000000427 antigen Substances 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 12
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 12
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 12
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 239000001608 potassium adipate Substances 0.000 claims description 2
- 239000001601 sodium adipate Substances 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022074378A JP2022105121A (ja) | 2017-02-10 | 2022-04-28 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457785P | 2017-02-10 | 2017-02-10 | |
| US62/457,785 | 2017-02-10 | ||
| PCT/US2018/017718 WO2018148610A1 (en) | 2017-02-10 | 2018-02-10 | Proteins binding psma, nkg2d and cd16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074378A Division JP2022105121A (ja) | 2017-02-10 | 2022-04-28 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507577A JP2020507577A (ja) | 2020-03-12 |
| JP2020507577A5 true JP2020507577A5 (enExample) | 2021-03-25 |
Family
ID=63107819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543270A Withdrawn JP2020507577A (ja) | 2017-02-10 | 2018-02-10 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
| JP2022074378A Withdrawn JP2022105121A (ja) | 2017-02-10 | 2022-04-28 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074378A Withdrawn JP2022105121A (ja) | 2017-02-10 | 2022-04-28 | Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200024353A1 (enExample) |
| EP (1) | EP3579878A4 (enExample) |
| JP (2) | JP2020507577A (enExample) |
| KR (1) | KR20190120770A (enExample) |
| CN (1) | CN110913902A (enExample) |
| AU (1) | AU2018217834A1 (enExample) |
| BR (1) | BR112019016553A2 (enExample) |
| CA (1) | CA3053275A1 (enExample) |
| IL (1) | IL268574A (enExample) |
| MX (1) | MX2019009541A (enExample) |
| RU (1) | RU2019128204A (enExample) |
| SG (1) | SG11201907271PA (enExample) |
| WO (1) | WO2018148610A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020506971A (ja) | 2017-02-08 | 2020-03-05 | ドラゴンフライ セラピューティクス， インコーポレイテッド | ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用 |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| PE20210375A1 (es) | 2018-02-08 | 2021-03-02 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales |
| MX2020008684A (es) | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso. |
| JP7482363B2 (ja) | 2018-08-08 | 2024-05-14 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| US12384851B2 (en) | 2018-08-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN117881702A (zh) * | 2021-08-03 | 2024-04-12 | 山东先声生物制药有限公司 | 一种cd16抗体及其应用 |
| CN117915950A (zh) * | 2021-08-06 | 2024-04-19 | 甘李药业股份有限公司 | 一种多特异性抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1423700A (zh) * | 2000-03-24 | 2003-06-11 | 麦克美特股份公司 | 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽 |
| US6455712B1 (en) * | 2000-12-13 | 2002-09-24 | Shell Oil Company | Preparation of oxirane compounds |
| US20070071759A1 (en) * | 2005-06-29 | 2007-03-29 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| JP2009514537A (ja) * | 2005-11-03 | 2009-04-09 | ジェネンテック・インコーポレーテッド | 治療的抗ｈｅｒ２抗体融合ポリペプチド |
| AU2007257692B2 (en) * | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| PL2222706T5 (pl) * | 2007-12-14 | 2017-09-29 | Novo Nordisk As | Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania |
| EP2419451A4 (en) * | 2009-04-14 | 2012-11-14 | Proscan Rx Pharma Inc | ANTIBODIES DIRECTED AGAINST THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2011130499A1 (en) * | 2010-04-15 | 2011-10-20 | Genentech, Inc. | Anti-polyubiquitin antibodies and methods of use |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| US9321844B2 (en) * | 2011-08-05 | 2016-04-26 | Genentech, Inc. | Anti-polyubiquitin antibodies |
| US20140323315A1 (en) * | 2013-04-29 | 2014-10-30 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| EP3152235B1 (en) * | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| SG11201703803WA (en) * | 2014-11-11 | 2017-06-29 | Amunix Operating Inc | Targeted xten conjugate compositions and methods of making same |
| EP3243837A4 (en) * | 2015-01-08 | 2018-12-05 | Kyowa Hakko Kirin Co., Ltd. | Bispecific antibody binding to trailr2 and psma |
| JP2018503399A (ja) * | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| WO2016134371A2 (en) * | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| WO2016135041A1 (en) * | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| DK3280432T3 (da) * | 2015-04-06 | 2021-04-26 | Subdomain Llc | Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf |
| AU2016284866B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific antigen binding proteins |
-
2018
- 2018-02-10 EP EP18751484.9A patent/EP3579878A4/en not_active Withdrawn
- 2018-02-10 KR KR1020197026585A patent/KR20190120770A/ko not_active Withdrawn
- 2018-02-10 RU RU2019128204A patent/RU2019128204A/ru unknown
- 2018-02-10 CN CN201880024146.6A patent/CN110913902A/zh active Pending
- 2018-02-10 MX MX2019009541A patent/MX2019009541A/es unknown
- 2018-02-10 AU AU2018217834A patent/AU2018217834A1/en not_active Abandoned
- 2018-02-10 US US16/483,788 patent/US20200024353A1/en not_active Abandoned
- 2018-02-10 CA CA3053275A patent/CA3053275A1/en active Pending
- 2018-02-10 BR BR112019016553-3A patent/BR112019016553A2/pt not_active Application Discontinuation
- 2018-02-10 SG SG11201907271PA patent/SG11201907271PA/en unknown
- 2018-02-10 WO PCT/US2018/017718 patent/WO2018148610A1/en not_active Ceased
- 2018-02-10 JP JP2019543270A patent/JP2020507577A/ja not_active Withdrawn
-
2019
- 2019-08-07 IL IL268574A patent/IL268574A/en unknown
-
2022
- 2022-04-28 JP JP2022074378A patent/JP2022105121A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507577A5 (enExample) | ||
| JP2020510646A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2020507328A5 (enExample) | ||
| JP2023052214A5 (enExample) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021098733A5 (enExample) | ||
| JP2023106433A5 (enExample) | ||
| JP2020521448A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| AU2022201375B2 (en) | Antigen-specific t cells and uses thereof | |
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 | |
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2020522474A5 (enExample) | ||
| JP2020522473A5 (enExample) | ||
| JP2020529410A5 (enExample) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2017535257A5 (enExample) | ||
| JP2020536532A5 (enExample) | ||
| JP2020531525A5 (enExample) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2020514277A5 (enExample) | ||
| JP2018510617A5 (enExample) |